Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
37 hedge funds and large institutions have $233M invested in Sierra Oncology, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
38% more capital invested
Capital invested by funds: $169M → $233M (+$63.9M)
9% more funds holding
Funds holding: 34 → 37 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$12M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.11M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$5.91M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.59M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$4.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$1.56M |
| 2 |
PA
Perceptive Advisors
New York
|
-$1.3M |
| 3 |
TI
Telemetry Investments
New York
|
-$241K |
| 4 |
Millennium Management
New York
|
-$160K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$139K |
SRRA Hedge Fund Activity: Q3 2021 in Review
37 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q3 2021, worth a combined $233M — up 38% from $169M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SRRA positions and 3 closed out — a net gain of 4 holders — while 13 added to existing stakes and 7 trimmed.
The largest buyer was Frazier Management, adding an estimated $12M. The largest seller was Nan Fung Group Holdings, cutting an estimated $1.56M.
- 37 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q3 2021, up from 34 in Q2 2021.
- Funds reported $233M of Sierra Oncology, Inc. Common Stock stock for Q3 2021, up 38% quarter-over-quarter.
- 7 funds opened new Sierra Oncology, Inc. Common Stock positions in Q3 2021 and 3 closed out, a net change of +4 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q3 2021 was Frazier Management, an estimated $12M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q3 2021 was Nan Fung Group Holdings, an estimated $1.56M sold.
Based on aggregated 13F filings for Q3 2021.